Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma
Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
:This is a an open-label, single-arm study to evaluate the efficacy and safety of zanubrutinib and G-CHOP in untreated Intermediate-high risk Follicular Lymphoma patients.
Phase:
PHASE2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital